BLTE

MKT CAP:$6B

Belite Bio, Inc

Market Cap

$6B

Healthcare·Biotechnology·🇺🇸 United States·NASDAQ

Healthcare·Biotechnology·🇺🇸·NASDAQ

Stock Price

$167.42+$8.15 (+5.12%)

Apr 22, 2026

Company Details

Belite Bio, Inc, a clinical-stage biopharmaceutical drug development company, engages in the research and development of novel therapeutics targeting atrophic age-related macular degeneration and autosomal recessive stargardt diseases. Its ...

CEO

Yu-Hsin Lin

IPO Date

Apr 29, 2022

Website

belitebio.com

Key Metrics TTM

Revenue

$0

— YoY

Net Income

-$25M

EPS (Diluted)

-$0.72

Free Cash Flow

-$11M

Revenue / Share

$0.00

Gross Margin

—

Operating Margin

—

Net Margin

—

FCF Margin

—

P/S

—

P/E

—

Earnings Reports

Q1 2026

May 12, 2026

PENDING

FY 2025

Mar 31, 2026

$0EPS -$2.31

Q4 2025

Mar 31, 2026

$0EPS -$0.72

Q3 2025

Dec 1, 2025

$0EPS -$0.65

FY 2024

Mar 17, 2025

$0EPS -$1.18

Revenue & Profitability

Quarter	Revenue	Gross Profit	Operating Income
Q2 24	$0	$0	-$10M
Q3 25	$0	$0	-$23M
Q4 25	$0	$0	-$28M

Operating Cash Flow

Quarter	Operating CF	Free CF
Q2 24	$0	$0
Q4 25	-$10M	-$11M

Capital Expenditures

Quarter	CapEx
Q2 24	$0
Q4 25	$178.0K

CapEx

Stock-Based Compensation

Quarter	SBC ($)	% of Revenue
Q2 24	$0	—
Q4 25	$12M	—

OpEx Breakdown

Quarter	R&D	G&A
Q2 24	$9M	$1M
Q3 25	$10M	$13M
Q4 25	$15M	$13M

War Chest

Quarter	Cash	Short-term Investments	Total
Q1 22	$0	$35M	$35M
Q2 22	$48.7K	$0	$48.7K
Q3 22	$42.1K	$0	$42.1K
Q4 22	$42M	$0	$42M
Q1 23	$38M	$0	$38M
Q2 23	$57M	$0	$57M
Q3 23	$55M	$0	$55M
Q4 23	$88M	$0	$88M
Q1 24	$96M	$0	$96M
Q2 24	$96M	$0	$96M
Q3 24	$0	$0	$0
Q4 24	$32M	$113M	$145M
Q1 25	$0	$0	$0
Q2 25	$0	$0	$0
Q3 25	$157M	$119M	$276M
Q4 25	$353M	$139M	$492M

Shares Outstanding

Quarter	Shares (Diluted)	QoQ Change	YoY Change
Q2 24	30M	—	—
Q3 25	33M	+9.6%	—
Q4 25	34M	+0.9%	—

Shares Outstanding

Revenue Per Employee

Period	Revenue/Employee	Employees
Q2 24	$0	20
Q3 25	$0	25
Q4 25	$0	25

Revenue / Employee